Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 11Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 10Breast Neoplasms 10Uterine Cervical Neoplasms 9Lymphoma 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Sarcoma 5Melanoma 5Lymphoma, Follicular 5Leukemia 5Colorectal Neoplasms 5Adenocarcinoma of Lung 5Small Cell Lung Carcinoma 4Rectal Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Glioblastoma 4Central Nervous System Neoplasms 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 3

Interventions

Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Cyclosporine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Anemia, Refractory × Radiotherapy × Clear all
NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Mesoblast, Ltd.

Phase 2 Withdrawn
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡